Possible prognostic role of IL-17R in osteosarcoma |
| |
Authors: | Maria Cristina Honorati Luca Cattini Andrea Facchini |
| |
Affiliation: | (1) Dipartimento di Medicina Interna e Gastroenterologia, Università di Bologna, Via Massarenti 9, 40136 Bologna, Italy;(2) Laboratorio di Immunologia e Genetica, Istituto di Ricerca Codivilla Putti, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy |
| |
Abstract: | Purpose An intense vascularization of primary tumor mass is associated with a fatal outcome in various types of invasive solid tumors. Interleukin 17 (IL-17), a CD4+ T-cell-derived cytokine, stimulates some tumor cells to secrete angiogenic factors, among which venous endothelial growth factor (VEGF). We assessed whether the expression of IL-17 receptor (IL-17R) represents a marker for the metastasizing ability of osteosarcoma (OS), a very malignant bone tumor. Methods We immunoassayed the amount of VEGF secreted by three OS cell lines expressing IL-17R in differing amounts: HOS, MG63 and U-2 OS, and their sensitivity to IL-17 stimulation to secrete VEGF. Results U-2 OS, which best expresses IL-17R, secreted the highest amounts of VEGF and was the most sensitive to IL-17, whereas MG63 expressed the lowest level of IL-17R, secreted the lowest amount of VEGF and was not sensitive to IL-17. IL-17R expression correlated with VEGF secretion and IL-17 sensitivity. U-2 OS expressed the most dedifferentiated phenotype, which is associated with tumor malignancy. Conclusions These results suggest that IL-17R in OS might represent a marker of tumor metastasis potential. |
| |
Keywords: | Osteosarcoma IL-17R Malignancy marker VEGF |
本文献已被 PubMed SpringerLink 等数据库收录! |
|